Market Research Logo

Global Hyperphosphatemia Drug Market Forecast 2019-2027

Global Hyperphosphatemia Drug Market Forecast 2019-2027

KEY FINDINGS

The global hyperphosphatemia drugs market is expected to grow at a CAGR of 16.13% during the forecast period of 2019-2027. The market is expected to be worth $xx million by the year 2027. Increasing prevalence of chronic diseases, unmet medical needs, a high proportion of the elderly population and the rise in public awareness are the major drivers for the hyperphosphatemia drugs market.

MARKET INSIGHTS

The market segmentation is done on the basis of the formulation. The various types of phosphate binders include calcium-based phosphate binders, aluminium-based phosphate binders, magnesium-based phosphate binders, iron-based phosphate binders and other phosphate binders. Of these, the Calcium-based phosphate binder’s held the largest market share of xx% in 2018 and is expected to continue its dominance during the forecast period. The global hyperphosphatemia market is facing many restraints due to various limitations levied by the Food and Drug Administration (FDA) and the growing side effects of the hyperphosphatemia drugs observed in some patients. In spite of this, the Asia-Pacific hyperphosphatemia drug market is showing much promise in terms of making various opportunities available for the market to grow and expand.

REGIONAL INSIGHTS

The hyperphosphatemia drugs market in North America is expected to hold the largest share by the end of the forecast period due to changing dietary habits, increasing osteoporosis cases and a rising ageing population in this region. The Europe hyperphosphatemia drugs market is also fast growing at a CAGR of xx%. However, it is the Asia-Pacific market which is expected to propel the market growth, with the Indian hyperphosphatemia drugs market exhibiting the highest growth at a CAGR of xx% during the forecast period.

COMPETITIVE INSIGHTS

The major companies in the hyperphosphatemia drugs market include, Johnson And Johnson, Amag Pharmaceuticals, Cipla, Keryx Biopharmaceuticals, Sun Pharm Inc., Zeria Pharmaceutical, DSM Biotech Pharmacal , Ultragenyx, Fermenta Biotech Ltd, Pfizer Inc., Bruno Pharmaceutical Spa, Roche Diagnostics Corporation, Vifor Pharma, Sanofi R.H. Moore Drug Co., Shire, and Fresenius Medical Care.


1. Research Scope
1.1. Study Goals
1.2. Scope Of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study And Forecasting Years
2. Research Methodology
2.1. Sources Of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top Down Approach
2.3. Bottom-up Approach
2.4. Data Triangulation
2.5. Estimation Methodology
3. Executive Summary
3.1. Market Summary
3.2. Key Findings
3.2.1. China Is The Largest Healthcare Drugs And Equipment Market In Asia-pacific Region
3.2.2. Iron-based Hyperphosphatemia Drugs Is A Game Changer
4. Market Determinants
4.1. Market Scope & Definition
4.2. Drivers
4.2.1. Growing Prevalence Of Chronic Diseases
4.2.2. Unmet Medical Needs
4.2.3. Skewed Population Mix Towards Elderly People
4.2.4. Rise In Public Awareness
4.3. Restraints
4.3.1. Limitations Levied By The Food And Drug Administration (Fda)
4.3.2. Growing Side Effects Of The Hyperphosphatemia Drugs
4.4. Opportunities
4.4.1. Asia Pacific Regions Are Expected To Propel The Market Growth
4.5. Challenges
4.5.1. Non-adherence To Treatment Regimens
4.5.2. Side Effects Of Drugs
4.5.3. Limited Availability Of Drugs
4.5.4. Use Of Advanced Dialysis Techniques
4.6. Market By Dosage
4.6.1. Solid
4.6.1.1. Tablet
4.6.1.2. Powder
4.6.2. Liquid
4.6.2.1. Solution
5. Market By Formulation
5.1.1. Calcium-based Phosphate Binders
5.1.2. Aluminum-based Phosphate Binders
5.1.3. Magnesium-based Phosphate Binders
5.1.4. Iron-based Phosphate Binders
5.1.5. Other Phosphate Binders
6. Key Analytics
6.1. Porter’s Five Force Model
6.1.1. Threat Of New Entrants
6.1.2. Bargaining Power Of Buyers
6.1.3. Bargaining Power Of Suppliers
6.1.4. Threat Of Substitute Product
6.1.5. Intensity Of Competitive Rivalry
6.2. Opportunity Matrix
6.3. Key Buying Criteria
6.3.1. Application
6.3.2. Pricing
6.3.3. Effectiveness
6.3.4. Availability
6.4. Strategic Recommendation & Strategic Conclusions
6.5. Market Trends
6.5.1. Patient Assistance Programs
6.5.2. Strategic Alliances
6.5.3. Increase In R&D
6.6. Phosphate Binders Usages Guidelines
7. Geographic Analysis
7.1. North America
7.1.1. The United States
7.1.2. Canada
7.2. Europe
7.2.1. The United Kingdom
7.2.2. France
7.2.3. Germany
7.2.4. Spain
7.2.5. Italy
7.2.6. Rest Of Europe (Roe)
7.3. Asia Pacific
7.3.1. India
7.3.2. China
7.3.3. Japan
7.3.4. Australia
7.3.5. South Korea
7.3.6. Rest Of Apac
7.4. Rest Of The World
7.4.1. Latin America
7.4.2. Middle East And America
8. Competitive Landscape
8.1. Market Share Analysis
8.2. Company Profiles
8.2.1. Amag Pharmaceuticals
8.2.1.1. Overview
8.2.1.2. Product Portfolio
8.2.1.3. Scot Analysis
8.2.1.4. Strategic Initiatives
8.2.2. Biotech Pharmacal
8.2.2.1. Overview
8.2.2.2. Products Portfolio
8.2.2.3. Scot Analysis
8.2.2.4. Strategic Initiatives
8.2.3. Bruno Farmaceutici Spa
8.2.3.1. Overview
8.2.3.2. Product Portfolio
8.2.3.3. Scot Analysis
8.2.3.4. Strategic Initiatives
8.2.4. Cipla
8.2.4.1. Overview
8.2.4.2. Product Portfolio
8.2.4.3. Scot Analysis
8.2.4.4. Strategic Initiatives
8.2.5. Fermenta Biotech Ltd
8.2.5.1. Overview
8.2.5.2. Product Portfolio
8.2.5.3. Scot Analysis
8.2.5.4. Strategic Initiatives
8.2.6. Fresenius Medical Care
8.2.6.1. Overview
8.2.6.2. Product Portfolio
8.2.6.3. Scot Analysis
8.2.6.4. Strategic Initiatives
8.2.7. Johnson And Johnson
8.2.7.1. Company Overview
8.2.7.2. Product Portfolio
8.2.7.3. Scot Analysis
8.2.7.4. Strategic Initiatives
8.2.8. Keryx Biopharmaceuticals Inc
8.2.8.1. Overview
8.2.8.2. Scot Analysis
8.2.8.3. Strategic Initiatives
8.2.9. Pfizer Inc.
8.2.9.1. Overview
8.2.9.2. Product Portfolio
8.2.9.3. Scot Analysis
8.2.9.4. Strategic Initiatives
8.2.10. Roche Diagnostics Corporation
8.2.10.1. Overview
8.2.10.2. Product Portfolio
8.2.10.3. Scot Analysis
8.2.10.4. Strategic Initiatives
8.2.11. Royal Dsm N.V.
8.2.11.1. Overview
8.2.11.2. Product Portfolio
8.2.11.3. Scot Analysis
8.2.11.4. Strategic Initiatives
8.2.12. Sanofi
8.2.12.1. Overview
8.2.12.2. Product Portfolio
8.2.12.3. Scot Analysis
8.2.12.4. Strategic Initiatives
8.2.13. Shire
8.2.13.1. Overview
8.2.13.2. Product Portfolio
8.2.13.3. Scot Analysis
8.2.13.4. Strategic Initiatives
8.2.14. Sun Pharmaceutical Industries Ltd
8.2.14.1. Overview
8.2.14.2. Products Portfolio
8.2.14.3. Scot Analysis
8.2.14.4. Strategic Initiatives
8.2.15. Ultragenyx Pharmaceutical Inc.
8.2.15.1. Overview
8.2.15.2. Product Portfolio
8.2.15.3. Scot Analysis
8.2.15.4. Strategic Initiatives
8.2.16. Zeria Pharmaceutical
8.2.16.1. Overview
8.2.16.2. Product Portfolio
8.2.16.3. Scot Analysis
8.2.16.4. Strategic Initiatives
List Of Tables
Table 1 Global Hyperphosphatemia Drug Market By Region 2019-2027($ Million)
Table 2 Iron-based Hyperphosphatemia Drug Approval Status 2014-2017
Table 3 Global Prevalence Of Diabetes 2015 And 2035 (Millions)
Table 4 Worldwide Population Aged 80 And Above 1950-2050 (Millions)
Table 5 Phosphorous Levels In Select Foods
Table 6 Global Hyperphosphatemia Drugs Market By Formulation 2019-2027($ Million)
Table 7 Global Calcium-based Phosphate Binders By Region 2019-2027($ Million)
Table 8 Global Aluminum-based Phosphate Binders By Region 2019-2027($ Million)
Table 9 Global Magnesium-based Phosphate Binders By Region 2019-2027($ Million)
Table 10 Global Iron-based Phosphate Binders By Region 2019-2027($ Million)
Table 11 Global Other Phosphate Binders By Region 2019-2027($ Million)
Table 12 Pipeline Portfolio Of Hyperphosphatemia Drugs
Table 13 Global Hyperphosphatemia Drugs Market By Region 2019-2027 ($ Million)
Table 14 North America Hyperphosphatemia Drugs Market By Country 2019-2027($ Million)
Table 15 Europe Hyperphosphatemia Drugs Market By Country 2019-2027($ Million)
Table 16 Asia-pacific Hyperphosphatemia Drugs Market By Country 2019-2027($ Million)
Table 17 Per Capita Consumption Of Dairy Products In Australia 2014 -2016
Table 18 Rest Of The World Hyperphosphatemia Drugs Market By Country 2019-2027($ Million)
List Of Figures
Figure 1 Rate Of Adherence To Phosphate Binders
Figure 2 Diagnosis And Clinical Indicators Of Chronic Kidney Disease
Figure 3 Global Hyperphosphatemia Drugs Market By Calcium-based Phosphate Binders 2019-2027($ Million)
Figure 4 Global Hyperphosphatemia Drugs Market By Aluminum-based Phosphate Binders 2019-2027($ Million)
Figure 5 Global Hyperphosphatemia Drugs Market By Magnesium-based Phosphate Binders 2019-2027($ Million)
Figure 6 Global Hyperphosphatemia Drugs Market By Iron-based Phosphate Binders 2019-2027($ Million)
Figure 7 Global Hyperphosphatemia Drugs Market By Other Phosphate Binders 2019-2027($ Million)
Figure 8 Porters 5 Force Model Of Hyperphosphatemia Market
Figure 9 Investment Preposition Across Regions 2019-2027
Figure 10 Global Hyperphosphatemia Drugs Market Share, By Region 2019 & 2027 (%)
Figure 11 North America Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 12 The United States Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 13 Canada Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 14 Europe Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 15 The United Kingdom Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 16 France Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 17 Germany Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 18 Spain Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 19 Italy Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 20 Rest Of Europe Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 21 Asia-pacific Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 22 Age Wise Distribution Of Elderly Population In India 2016
Figure 23 India Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 24 China Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 25 Japan Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 26 Number Of Fractures Due To Osteoporosis And Osteopenia ($ Million)
Figure 27 Australia Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 28 South Korea Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 29 Roapac Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 30 Rest Of The World Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 31 Latin America Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 32 Mena Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 33 Market Share Analysis Of Key Players 2017 (%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report